Nurix Therapeutics (NASDAQ:NRIX) Hits New 1-Year High – Should You Buy?

Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) reached a new 52-week high during mid-day trading on Thursday . The company traded as high as $24.97 and last traded at $24.8810, with a volume of 114976 shares changing hands. The stock had previously closed at $24.31.

Nurix Therapeutics News Summary

Here are the key news stories impacting Nurix Therapeutics this week:

• Positive Sentiment: Roche collaboration news was a major catalyst: Nurix said it entered a global partnership for bexobrutideg with potential total payments of up to $2.3 billion, including a $700 million upfront payment. Nurix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
• Positive Sentiment: Royal Bank of Canada raised its price target on Nurix Therapeutics from $30 to $33 and reiterated an outperform rating, signaling confidence in upside from current levels.
• Positive Sentiment: Stifel Nicolaus lifted its target from $34 to $40 and maintained a buy rating, while Needham and BTIG also reaffirmed buy ratings with targets of $34 and $32, respectively, adding to the bullish analyst tone.
• Neutral Sentiment: Nurix reported second-quarter 2026 results with an EPS loss of $0.81 and revenue of $9.04 million, both below estimates, which kept focus on the company’s pipeline and partnership potential rather than near-term fundamentals. Nurix Therapeutics, Inc.: Nurix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
• Negative Sentiment: The earnings miss may cap enthusiasm somewhat, as the company posted a wider loss than expected and revenue came in well below consensus. Nurix Therapeutics, Inc. (NRIX) Reports Q2 Loss, Lags Revenue Estimates

Wall Street Analyst Weigh In

NRIX has been the topic of a number of analyst reports. Truist Financial lifted their price objective on Nurix Therapeutics from $32.00 to $34.00 and gave the stock a “buy” rating in a research report on Friday. Oppenheimer assumed coverage on Nurix Therapeutics in a report on Monday, June 29th. They set an “outperform” rating and a $28.00 price target for the company. Stifel Nicolaus lifted their price target on shares of Nurix Therapeutics from $34.00 to $40.00 and gave the company a “buy” rating in a research report on Friday. Wells Fargo & Company cut Nurix Therapeutics from an “overweight” rating to a “hold” rating and dropped their price objective for the company from $28.00 to $25.00 in a research note on Monday, June 8th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Nurix Therapeutics in a research report on Tuesday, April 21st. Twelve investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Nurix Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $33.77.

Nurix Therapeutics Stock Down 6.6%

The firm has a market cap of $2.38 billion, a PE ratio of -7.30 and a beta of 1.80. The business has a 50-day moving average price of $18.44 and a two-hundred day moving average price of $17.37.

Nurix Therapeutics (NASDAQ:NRIX) last released its earnings results on Thursday, July 9th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.09). Nurix Therapeutics had a negative net margin of 928.44% and a negative return on equity of 73.57%. The company had revenue of $9.04 million during the quarter, compared to analysts’ expectations of $15.29 million. On average, equities research analysts predict that Nurix Therapeutics, Inc. will post -2.88 earnings per share for the current fiscal year.

Insider Transactions at Nurix Therapeutics

In other news, CFO Houte Hans Van sold 14,055 shares of Nurix Therapeutics stock in a transaction dated Tuesday, May 5th. The stock was sold at an average price of $16.60, for a total value of $233,313.00. Following the completion of the transaction, the chief financial officer owned 37,592 shares in the company, valued at approximately $624,027.20. This trade represents a 27.21% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Gwenn Hansen sold 5,394 shares of the business’s stock in a transaction dated Thursday, June 25th. The stock was sold at an average price of $20.00, for a total value of $107,880.00. Following the transaction, the insider directly owned 115,005 shares of the company’s stock, valued at approximately $2,300,100. This represents a 4.48% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 25,051 shares of company stock worth $434,466 in the last ninety days. 6.70% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. General Atlantic L.P. purchased a new stake in Nurix Therapeutics during the fourth quarter worth approximately $92,899,000. Vanguard Group Inc. boosted its holdings in Nurix Therapeutics by 32.5% in the fourth quarter. Vanguard Group Inc. now owns 5,949,512 shares of the company’s stock valued at $112,862,000 after purchasing an additional 1,460,736 shares in the last quarter. Baker BROS. Advisors LP increased its stake in Nurix Therapeutics by 20.0% in the fourth quarter. Baker BROS. Advisors LP now owns 4,658,556 shares of the company’s stock valued at $88,373,000 after purchasing an additional 776,431 shares during the last quarter. Flax Pond Capital LLC purchased a new position in Nurix Therapeutics in the fourth quarter valued at approximately $1,521,000. Finally, Perceptive Advisors LLC raised its holdings in Nurix Therapeutics by 151.1% during the fourth quarter. Perceptive Advisors LLC now owns 3,555,877 shares of the company’s stock worth $67,455,000 after purchasing an additional 2,139,728 shares in the last quarter.

About Nurix Therapeutics

Nurix Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that harness the ubiquitin-proteasome system to selectively degrade disease-causing proteins. By modulating E3 ubiquitin ligases and related molecular machinery, Nurix aims to expand treatment options for patient populations with unmet medical needs in oncology and immunology.

The company’s pipeline includes multiple programs in various stages of development.